The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

Therapeutic compounds containing an arylacetamide core pending N-benzyl group. Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for inhibiting AMP-activated kinase (AMPK) and their use thereof for treating breast and pancreatic cancer with the specified compounds.

Therapeutic compounds containing an arylacetamide core pending N-benzyl group. Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for inhibiting AMP-activated kinase (AMPK) and their use thereof for treating breast and pancreatic cancer with the specified compounds.

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein Z, X, R.sup.1, R.sup.2, W, R.sup.3, R.sup.4a, R.sup.4b, L, R.sup.5a, R.sup.5b and Q are as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein Z, X, R.sup.1, R.sup.2, W, R.sup.3, R.sup.4a, R.sup.4b, L, R.sup.5a, R.sup.5b and Q are as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.